In human RA, DEX inhibits migration, invasion, and inflammation of fibroblast-like synoviocytes by decreasing the NLRC5 level, which will further inhibit NF-κB pathway [191]. The gene discussed is NLRC5; the disease is rheumatoid arthritis.